On the other hand, IGF1R inhibitor alleviated pain behaviors [35], attenuated hyperalgesia [36], and teprotumumab (IGF1R inhibitor) reduced proptosis, the Clinical Activity Score and improved quality of life in patients with thyroid associate ophthalmopathy [39]. This evidence concerns the gene IGF1R and Graves ophthalmopathy.